Product Description: Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].
Applications: Cancer-programmed cell death
Formula: C47H55ClF3N5O6S3
References: [1]Lock R1, et al. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jun;50(6):1181-1189./[2]Wong M, et al. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.Mol Cancer Ther. 2012 Apr;11(4):1026-1035./[3]Chen J, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9.
CAS Number: 923564-51-6
Molecular Weight: 974.61
Compound Purity: 99.97
Research Area: Cancer
Solubility: DMF : ≥ 100 mg/mL/DMSO : 75 mg/mL (ultrasonic)
Target: Bcl-2 Family
Deutsch
English
